Salute e Benessere

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with…

GENFIT completes a royalty financing of up to €185 million with HCRx after unanimous OCEANE bondholder approval, triggering a €130 million upfront payment with potential for an additional €55 million upon achieving near-term milestonesNon-dilutive financing extends cash runway beyond 2027 and supports GENFIT's R&D effortsFinancing strengthens GENFIT's ACLF pipeline development and commitment to transformative therapiesGENFIT to use €61.66 million to repurchase 1,882,891 2025...
Nasdaq GlobeNewswire
20/03/2025

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating…

Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients with unresectable, locoregional recurrent NSCLC to be presented by principal investigator Dr. Saumil Gandhi at 8:00 AM EDT / 1:00 PM CET on Friday March 28 th, 2025Data evaluating safety and injection feasibility from a Phase 1 study of JNJ-1900 (NBTXR3) in combination nivolumab or pembrolizumab...
Nasdaq GlobeNewswire
20/03/2025

Kahf & Wardah Support Open Iftar London 2025: Strengthening Global Brotherhood

Kahf contributed to the event by presenting notable Muslim creators, including Waseem's Way (Content Creator & Influencer), Josh Lamonaca (Men's Hair Educator of the Year 2024), and Jihar Gifari (Indonesian AI & Data Science Expert), showcasing the harmony of self-care, faith, and success globally. Kahf contributed to the event by presenting notable Muslim creators, includingWaseem's Way(Content Creator & Influencer), Josh Lamonaca (Men's Hair Educator of the Year 2024), andJihar...
PR Newswire
20/03/2025

Oclean Advocates a Scientific Oral Care Routine

Through 3 years of research into users' oral care habits, Oclean offers the following 6-Step Scientific Oral Care Routine to improve the level of oral hygiene care Through 3 years of research into users' oral care habits, Oclean offers the following6-Step Scientific Oral Care Routineto improve the level of oral hygiene care Step 1: Tongue Cleaning– Clean your tongue from night coating and volatile sulfur compounds with a scraper in the morning.Step 2: Dental Flossing– Use dental...
PR Newswire
20/03/2025

Zealand Pharma increases its share capital as a result of the exercise of…

Company announcement – No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrantsCopenhagen, Denmark, March 20, 2025 –Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 27,425 divided into 27,425 new shares with a nominal...
Nasdaq GlobeNewswire
20/03/2025

Evestia Clinical - the new brand identity for EMAS Pharma - launches today as a…

"The launch of Evestia Clinical marks an exciting new chapter in our journey," saidRichard Barfield, Chairman of Evestia Clinical. "Our leadership team has a proven track record of driving growth in the CRO sector, and with the support of Kester Capital, we are well-positioned to accelerate our expansion, strengthen our service offerings, and broaden our global reach. We are building a world-class platform that will deliver exceptional value to our biotech clients. "Our…
PR Newswire
20/03/2025

Menarini Group Announces Collaboration with VisualDx to Aid in Identifying…

BPDCN is an aggressive orphan hematologic malignancy with a historically poor prognosis (approximately 8.7 to 14 months post diagnosis[1]) that typically presents skin lesions and can also involve the bone marrow, blood, central nervous system, lymph nodes and viscera. Dermatologists may be the first to recognize the signs of BPDCN and biopsy suspicious lesions. Pathologists can then test for BPDCN by testing for certain biomarkers which are highly expressed on BPDCN cells. Tagraxofusp-erzs is…
PR Newswire
20/03/2025

US Remote Patient Monitoring Market worth US$29.13 billion by 2030 with 12.8%…

Browse in-depth TOC on "Remote Patient Monitoring Market" Browse in-depth TOC on "Remote Patient Monitoring Market" 200 - Tables50 - Figures395 - Pages By Based on component,the US remote patient monitoring market has been segmented into devices, software and services. In 2023, device segment is estimated to hold the largest share in the US remote patient monitoring market. Recent innovations in the US remote patient monitoring (RPM) market such as inMarch 2024,...
PR Newswire
20/03/2025

AZmed to Improve Pediatric and Emergency Radiology in Canada

UP isCanada'sfirst specialized pediatric emergency center outside of a hospital, providing urgent care as emergency rooms continue to fill to capacity and face growing wait times. Committed to the belief that children should receive top-notch care, UP is focused on transforming healthcare throughoutCanada. ‍"AZtrauma is a great solution that, in our model of care, enables patients to get their diagnostic imaging and return to the treating pediatric emergency physician, who is...
PR Newswire
20/03/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 20 MARCH 2025 at 15.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on...
Nasdaq GlobeNewswire
20/03/2025

Seegene Unveils HPV Genotyping Solution at EUROGIN 2025

The company showcased its expertise through an exhibition booth under the theme "Elevating Confidence in HPV Screening" and hosted symposium programs to emphasize accurate identification of high-risk HPV types related to cervical cancer is critical. Seegene's advanced solution enhances diagnostic accuracy, enabling timely and effective detection. The company showcased its expertise through an exhibition booth under the theme "Elevating Confidence in HPV Screening" and hosted…
PR Newswire
20/03/2025

Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for…

"We are happy to support AtomVie in advancing global radiopharmaceutical development programs with Theralugand®," stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. "By providing our high-quality radionuclides, we vitally contribute to the further development of therapeutic approaches in nuclear medicine." "We are happy to support AtomVie in advancing global radiopharmaceutical development programs with Theralugand ®," stated Dr.Harald Hasselmann, CEO of…
PR Newswire
20/03/2025

Coronado Research Announce the Appointment of Gary Lyons as EVP Medical Affairs

Gary Lyons commented, "Medical Affairs is a central and critical function within pharma, increasingly bridging clinical development and commercial teams. Working cross-functionally, Medical Affairs optimises trial design, turns clinical data into impactful narrative and ensures the value proposition of an asset is fully evidenced across the drug lifecycle. From an external perspective, there is an increasing need for Medical Affairs to not only engage key stakeholders with the right data…
PR Newswire
20/03/2025

New Study Reveals NatureKnit™, a Patented, Natural Microbiome Ingredient…

"This research is an excellent illustration of how gut simulation models enable us to fully comprehend the behavior of functional ingredients in relation to the microbiome," said Massimo Marzorati, PhD, CEO of ProDigest and Faculty of CMET at Ghent University. "By replicating the human gut's complexity, we can create detailed insights that close the gap between laboratory research and actual applications." "This research is an excellent illustration of how gut simulation…
PR Newswire
20/03/2025

IM Cannabis to Report Fourth Quarter and Full Year 2024 Financial Results on…

If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com within 24 hours after the call. If you are unable to join us live, a recording of the call will be available on our website athttps://investors.imcannabis.comwithin 24 hours after the call. Link to register for the zoom call:https://us02web.zoom.us/webinar/register/WN_RJjroBAjSOSRZLqGuM8CCw About IM Cannabis Corp. IMC (Nasdaq: IMCC) (CSE: IMCC) is an...
PR Newswire
20/03/2025

Koelis Announces Innovative Products at EAU 2025 enhancing MRI Fusion Biopsy…

thEuropean Urology Meeting EAU as a major sponsor and exhibitor.Koelis will be holding interactive demonstrations at its booth #C40 from March 21 stto March 24 thto promote the innovative approach of using its exclusive “Organ Based Tracking” fusion technology in transperineal focal therapy of prostate cancer.Fusion biopsy and patient follow-up with 3D mapping are the cornerstone of a successful Focal Therapy program. In line with the latest EAU guidelines, Koelis Trinity ®is a...
Nasdaq GlobeNewswire
20/03/2025

Amphista Therapeutics to present novel mechanism of action for the degradation…

Amphista Therapeutics to present novel mechanism of action for the degradation of BRD9 using its proprietary Targeted Glue® technology at two key upcoming scientific conferencesOral presentations will detail the rapid, deep and persistent degradation of BRD9 through the recruitment of DCAF16 using Amphista's Targeted Glue® technology. Cambridge, UK, 20 March 2025– Amphista Therapeutics, a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines,...
Nasdaq GlobeNewswire
20/03/2025

iOnctura commences randomized Phase II study in metastatic uveal melanoma

The Phase II open label, randomized, parallel-arm OCULE-01 study (NCT06717126), has been designed to assess roginolisib as a monotherapy with the primary objective to evaluate overall survival in patients. The study will have multiple sites across Europe and the US, enrolling approximately 85 patients with metastatic UM, who have progressed following at least one prior therapy. The Phase II open label, randomized, parallel-arm OCULE-01 study ( NCT06717126 ), has been designed to assess...
PR Newswire
20/03/2025

EndoArt Inventor Dr. Ofer Daphna to Deliver Keynote Lecture at World Cornea…

As one of the most prestigious conferences in the field, WCC attracts top-tier professionals and best practices, fostering collaboration and innovation in corneal care. This milestone presentation reinforces EyeYon Medical's commitment to transforming corneal care and expanding accessibility to innovative treatments worldwide. As one of the most prestigious conferences in the field, WCC attracts top-tier professionals and best practices, fostering collaboration and innovation in corneal care...
PR Newswire
20/03/2025

Infinitopes Strengthens Board with Two Biotech Leaders to Advance Precision…

Dan Menichella, incoming Non-Executive Director at Infinitopes, added: "I am honoured to join Infinitopes' Board of Directors at this exciting time for the company, as we begin the Phase I/IIa clinical trial in oesophageal cancer. Infinitopes is a highly innovative company with a strong commitment to cancer research. Its approach holds the promise to revolutionise cancer treatments for patients, and I am excited and committed to support Jonathan and the team as they embark on this…
PR Newswire
20/03/2025

Versameb AG Announces Grant of First Patent in China for "Signal Peptide with…

"We are thrilled to receive this patent in China, which highlights the innovative nature of our technology and strengthens our position in the rapidly evolving field of RNA therapeutics," said Klaas Zuideveld, Chief Executive Officer of Versameb AG. "This patent is a testament to our team's dedication and expertise in developing cutting-edge solutions to address unmet medical needs. We look forward to leveraging this technology to advance our pipeline and bring new therapies to…
PR Newswire
20/03/2025

Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate…

By leveraging Domain's expertise to address challenging GPCRs, DT-9046 represents a groundbreaking advancement in PAR2 modulation employing a differentiated mechanism of action, targeting an allosteric binding site to fine-tune GPCR function and boost efficacy against this complex target. Unlike other PAR2-targeting strategies, primarily biologics and full antagonists, DT-9046 is the first oral PAR2-targeting drug to reach pre-IND studies. Combined with its biased ligand approach, this strategy…
PR Newswire
20/03/2025

NTG Nordic Transport Group acquires DTK

Company announcement no. 5 – 25 20 March 2025 NTG Nordic Transport Groupacquires DTK NTG Nordic Transport Group A/S (“NTG”) has signed an agreement to acquire 100% of the shares in Danish-based DTK BE Holding ApS (“DTK”).DTK is a full-service, end-to-end logistics solutions provider specialising in full- and part-load general cargo and temperature-controlled road freight services. In addition, DTK offers logistics services and warehousing solutions for a range of...
Nasdaq GlobeNewswire
20/03/2025

Northern Karelia Cooperative Society (PKO) has chosen Aino's SaaS platform

Northern Karelia Cooperative Society (PKO), a customer members owned cooperative, has chosen the Aino SaaS platform as part of an initiative to enhance workforce well-being and improve work ability management. PKO operates in 13 municipalities, managing 127 business units. The agreement includes a total of 1600 employees and the Aino SaaS platform is in production use from the second quarter of 2025. "Employee well-being is always a top priority for us, vital to the operation and our...
Nasdaq GlobeNewswire
20/03/2025
Altri  Comunicati